Quantification of the spread of SARS-CoV-2 variant B.1.1.7 in Switzerland

Chaoran Chen, Sarah Nadeau, Ivan Topolsky, Marc Manceau, Jana S. Huisman, Kim Philipp Jablonski, Lara Fuhrmann, David Dreifuss, Katharina Jahn, Christiane Beckmann, Maurice Redondo, Christoph Noppen, Lorenz Risch, Martin Risch, Nadia Wohlwend, Sinem Kas, Thomas Bodmer, Tim Roloff, Madlen Stange, Adrian Egli, Isabella Eckerle, Laurent Kaiser, Rebecca Denes, Mirjam Feldkamp, Ina Nissen, Natascha Santacroce, Elodie Burcklen, Catharine Aquino, Andreia Cabral de Gouvea, Maria Moccia, Simon Grüter, Timothy Sykes, Lennart Opitz, Griffin White, Laura Neff, Doris Popovic, Andrea Patrignani, Jay Tracy, Ralph Schlapbach, Emmanouil T. Dermitzakis, Keith Harshman, Ioannis Xénarios, Henri Pegeot, Lorenzo Cerutti, Deborah Penet, Anthony Blin, Melyssa Elies, Christian L. Althaus, Christian Beisel, Niko Beerenwinkel, Martin Ackermann, Tanja StadlermedRxiv 2021 · DOI

Abstract

In December 2020, the United Kingdom (UK) reported a SARS-CoV-2 Variant of Concern (VoC) now named B.1.1.7 (Alpha). Based on initial data from the UK and later data from other countries, this variant was estimated to have a transmission fitness advantage of around 40-80%. This study aims to estimate the transmission fitness advantage and the effective reproductive number of B.1.1.7 through time based on data from Switzerland. We generated whole genome sequences from 11.8% of all confirmed SARS-CoV-2 cases in Switzerland between 14 December 2020 and 11 March 2021. Based on these data, we determine the daily frequency of the B.1.1.7 variant and quantify the variant’s transmission fitness advantage on a national and a regional scale. We estimate B.1.1.7 had a transmission fitness advantage of 43-52% compared to the other variants circulating in Switzerland during the study period. Further, we estimate B.1.1.7 had a reproductive number above 1 from 01 January 2021 until the end of the study period, compared to below 1 for the other variants. Specifically, we estimate the reproductive number for B.1.1.7 was 1.24 [1.07-1.41] from 01 January until 17 January 2021 and 1.18 [1.06-1.30] from 18 January until 01 March 2021 based on the whole genome sequencing data. From 10 March to 16 March 2021, once B.1.1.7 was dominant, we estimate the reproductive number was 1.14 [1.00-1.26] based on all confirmed cases. The observed increase in B.1.1.7 frequency in Switzerland during the study period is as expected based on observations in the UK. In absolute numbers, B.1.1.7 increased exponentially with an estimated doubling time of around 2-3.5 weeks.

Introduction

When a new viral variant emerges, public health officials face a critical question: Is the variant spreading faster because it is biologically more transmissible, or is it simply "lucky"—benefiting from superspreading events or specific travel patterns? In late 2020, the B.1.1.7 variant appeared to have a massive growth advantage in the UK. However, it was not immediately clear if this advantage would persist across different countries with varying social behaviors and non-pharmaceutical interventions (NPIs).

This study addresses the need for high-resolution, country-specific data to quantify the fitness advantage of B.1.1.7 in Switzerland. By analyzing the variant's trajectory, researchers sought to determine if existing lockdown measures were sufficient to stop its spread and to characterize the dynamics of its transition to dominance.

Methods and Data

Genomic Surveillance

The study is notable for its scale, characterizing approximately 11.8% of all confirmed Swiss cases during the study period (December 2020 – March 2021). Three primary data sources were utilized:

  1. Viollier AG: Provided 9,772 whole-genome sequences (5.3% of Swiss infections), offering excellent regional resolution.
  2. Dr Risch AG: Screened 12,019 samples via S-gene target failure (SGTF) and PCR for the 501Y mutation, providing strong coverage of Eastern Switzerland.
  3. University Hospital Geneva (HUG): Contributed 2,074 sequences, allowing for a high-resolution analysis of the Lake Geneva region.

Statistical Modeling

The authors employed a combination of genomic surveillance and statistical modeling to derive their estimates:

  • Logistic Growth Modeling: A logistic model was fitted to the daily frequency of B.1.1.7 to estimate the growth rate ($a$) and the sigmoid midpoint ($t_0$).
  • Comparative Modeling: To ensure robustness, both discrete-time and continuous-time models were used to derive the transmission fitness advantage ($f$). These two models were treated as "extremes" to bracket the likely true value.
  • $R_e$ Estimation: Using the "EpiEstim" framework, the researchers deconvolved case data to estimate the effective reproductive number ($R_e$) separately for B.1.1.7 and non-B.1.1.7 variants. This allowed them to observe how different "tracks" of the epidemic responded to policy changes, such as the tightening of measures on January 18, 2021.

Key Insights: The "Two-Track" Epidemic

The most striking insight from the data is that Switzerland was experiencing two different epidemics simultaneously. In early January 2021, total case numbers were falling, which may have created a false sense of security. In reality, the NPIs in place were successfully crushing the "old" variants ($R_e \approx 0.83$), while B.1.1.7 was quietly expanding exponentially ($R_e \approx 1.24$).

By comparing three independent datasets with different geographic biases, the authors found a consistent fitness advantage. This confirmed that B.1.1.7’s success was due to biological properties—likely increased ACE2 receptor affinity—rather than localized superspreading events. Furthermore, regional analysis showed that the Lake Geneva region was roughly two weeks ahead of the rest of the country in B.1.1.7 dynamics, potentially linked to the high volume of UK travelers visiting ski resorts in the nearby Valais region in late 2020.

Results and Impact

Transmission Advantage and Growth

B.1.1.7 was estimated to be 43-52% more transmissible than previous variants in Switzerland. This biological edge resulted in a doubling time for absolute case numbers of approximately 2 to 3.5 weeks. By mid-March 2021, B.1.1.7 reached a frequency of approximately 80%, effectively becoming the dominant strain in the Swiss epidemic.

Response to Interventions

Even after public health measures were tightened on January 18, 2021, the $R_e$ for B.1.1.7 only dropped slightly from 1.24 to 1.18. Because this value remained above the critical threshold of 1.0, the variant continued its exponential growth despite the measures that were successfully suppressing other strains.

Limitations and Future Outlook

While the study utilized large datasets, the diagnostic companies involved had uneven geographical footprints. Additionally, the models assume the fitness advantage remains constant over time, though this could fluctuate as population immunity builds or human behavior shifts.

The methods developed for this study have since been integrated into the CoV-Spectrum platform, enabling near real-time monitoring of new variants of concern. This infrastructure is vital for identifying future shifts in viral fitness and informing timely public health responses.

Summary updated

Abstract

Abstract Background In December 2020, the United Kingdom (UK) reported a SARS-CoV-2 Variant of Concern (VoC) which is now named B.1.1.7. Based on initial data from the UK and later data from other countries, this variant was estimated to have a transmission fitness advantage of around 40-80% [1, 2, 3]. Aim This study aims to estimate the transmission fitness advantage and the effective reproductive number of B.1.1.7 through time based on data from Switzerland. Methods We generated whole genome sequences from 11.8% of all confirmed SARS-CoV-2 cases in Switzerland between 14 December 2020 and 11 March 2021. Based on these data, we determine the daily frequency of the B.1.1.7 variant and quantify the variant’s transmission fitness advantage on a national and a regional scale. Results We estimate B.1.1.7 had a transmission fitness advantage of 43-52% compared to the other variants circulating in Switzerland during the study period. Further, we estimate B.1.1.7 had a reproductive number above 1 from 01 January 2021 until the end of the study period, compared to below 1 for the other variants. Specifically, we estimate the reproductive number for B.1.1.7 was 1.24 [1.07-1.41] from 01 January until 17 January 2021 and 1.18 [1.06-1.30] from 18 January until 01 March 2021 based on the whole genome sequencing data. From 10 March to 16 March 2021, once B.1.1.7 was dominant, we estimate the reproductive number was 1.14 [1.00-1.26] based on all confirmed cases. For reference, Switzerland applied more non-pharmaceutical interventions to combat SARS-CoV-2 on 18 January 2021 and lifted some measures again on 01 March 2021. Conclusion The observed increase in B.1.1.7 frequency in Switzerland during the study period is as expected based on observations in the UK. In absolute numbers, B.1.1.7 increased exponentially with an estimated doubling time of around 2-3.5 weeks. To monitor the ongoing spread of B.1.1.7, our plots are available online.
BibTeX
@misc{chen2021quantification,
  author = {Chaoran Chen and Sarah Nadeau and Ivan Topolsky and Marc Manceau and Jana S. Huisman and Kim Philipp Jablonski and Lara Fuhrmann and David Dreifuss and Katharina Jahn and Christiane Beckmann and Maurice Redondo and Christoph Noppen and Lorenz Risch and Martin Risch and Nadia Wohlwend and Sinem Kas and Thomas Bodmer and Tim Roloff and Madlen Stange and Adrian Egli and Isabella Eckerle and Laurent Kaiser and Rebecca Denes and Mirjam Feldkamp and Ina Nissen and Natascha Santacroce and Elodie Burcklen and Catharine Aquino and Andreia Cabral de Gouvea and Maria Moccia and Simon Grüter and Timothy Sykes and Lennart Opitz and Griffin White and Laura Neff and Doris Popovic and Andrea Patrignani and Jay Tracy and Ralph Schlapbach and Emmanouil T. Dermitzakis and Keith Harshman and Ioannis Xénarios and Henri Pegeot and Lorenzo Cerutti and Deborah Penet and Anthony Blin and Melyssa Elies and Christian L. Althaus and Christian Beisel and Niko Beerenwinkel and Martin Ackermann and Tanja Stadler},
  title = {{Quantification of the spread of SARS-CoV-2 variant B.1.1.7 in Switzerland}},
  year = {2021},
  doi = {10.1101/2021.03.05.21252520},
  howpublished = {medRxiv},
}
Figure